PRKCB and glioblastoma: Further analysis by protein interaction network and pathway enrichment indicated that AA may intervene in GBM proliferation, angiogenesis, and intervene in the treatment of GBM by inhibiting the molecular functions of the AKT1-PRKCB signaling pathway, modulating EGFR tyrosine kinase resistance, and affecting the binding of tumor necrosis factor receptor.